JQ17JunQiJun Qi, Ph.D.42.33789600000000-71.1072493000000066299Qi, Jun0000-0002-1461-3356Our research focuses on exploring novel therapeutic strategies for cancer through a multi-disciplinary approach, including synthetic chemistry, medicinal chemistry, chemical biology, and biology. We study gene regulatory pathways including epigenetic proteins, chromatin modification enzymes, and transcription factors. We start our effort with designing and developing novel small molecule inhibitors. Using chemical probes and chemical biology tools, we seek understanding of the biological relevance of these targets in cancer with the goal of establishing a biological rationale for cancer therapy. Located at Dana-Farber Cancer Institute, our ultimate goal is to develop compounds and strategies that can be used in cancer treatment.617/582-9031Assistant Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:trainingAtOrganizationeducational organizationprns:trainingLocationtraining locationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:degreeEarneddegree earnedDepartmentDivisionvivo:educationalTrainingeducation and trainingEducational TrainingGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:majorFieldmajor field of degreevivo:orcidIdORCID idvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson29511348Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJOncogeneCombined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene. 2018 05; 37(21):2850-2862.Oncogene2018-03-07T00:00:002018Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.29507391Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS, Bradner JENature chemical biologyFunctional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol. 2018 04; 14(4):405-412.Nat Chem Biol2018-03-05T00:00:002018Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.29581585Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong KK, Gray NS, Bradner JENature chemical biologyThe dTAG system for immediate and target-specific protein degradation. Nat Chem Biol. 2018 05; 14(5):431-441.Nat Chem Biol2018-03-26T00:00:002018The dTAG system for immediate and target-specific protein degradation.20871596Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JENatureSelective inhibition of BET bromodomains. Nature. 2010 Dec 23; 468(7327):1067-73.Nature2010-09-24T00:00:002010Selective inhibition of BET bromodomains.Co-Principal InvestigatorPrincipal Investigator2023-07-31QI, JUN2018-08-01EZH2 in cancer biology and novel inhibitorsR01CA222218Principal Investigator30102854Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NSACS chemical biologyStructural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol. 2018 09 21; 13(9):2438-2448.ACS Chem Biol2018-08-31T00:00:002018Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.21814200Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CRNatureRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 03; 478(7370):524-8.Nature2011-08-03T00:00:002011RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.21889194Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CSCellBET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.Cell2011-09-01T00:00:002011BET bromodomain inhibition as a therapeutic strategy to target c-Myc.30279226Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BRBloodSmall-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.Blood2018-10-02T00:00:002018Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.30422115Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NSeLifeTargeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.Elife2018-11-13T00:00:002018Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.30431433Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SAeLifeTargeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 11 15; 7.Elife2018-11-15T00:00:002018Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.30537514Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M, Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier KCancer cellResistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018 12 10; 34(6):922-938.e7.Cancer Cell2018-12-10T00:00:002018Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.23250418Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira MNature communicationsCatalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012; 3:1288.Nat Commun2012-01-01T00:00:002012Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.http://qilab.dana-farber.orgqi lab websiteD016271Chemicals & Drugs5259840.645748Proto-Oncogene Proteins c-mycD014230Chemicals & Drugs4699060.639735TriazolesD009687Chemicals & Drugs184058300.335939Nuclear ProteinsD014157Chemicals & Drugs2870121200.240011Transcription Factors30962579Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan DLeukemiaDevelopment and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019 11; 33(11):2685-2694.Leukemia2019-04-08T00:00:002019Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.D001381Chemicals & Drugs2173350.819945AzepinesMedicinePediatricsHematology/OncologyVA Med CentersAdult OncologyOncologyBoston Children's HospitalDana-Farber Cancer Institute31085176Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao JCancer cellBCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 05 13; 35(5):752-766.e9.Cancer Cell2019-05-13T00:00:002019BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.31111916Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL, Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RANeuro-oncologyA large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. Neuro Oncol. 2019 09 06; 21(9):1150-1163.Neuro Oncol2019-09-06T00:00:002019A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.SAA2ScottArmstrongScott A. Armstrong, M.D.,Ph.D.42.33743600000000-71.1054470000000015840Armstrong, ScottDavid G. Nathan Professor of PediatricsPGR1PaulRichardsonPaul Gerard Guy Richardson, M.B.,B.S.42.33789600000000-71.1072493000000065832Richardson, PaulR.J. Corman Professor of MedicineKCA1KennethAndersonKenneth Carl Anderson, M.D.42.33789600000000-71.107249300000008381Anderson, KennethKraft Family Professor of MedicineTH9TeruHideshimaTeru Hideshima, M.D., Ph.D.42.33789600000000-71.1072493000000085624Hideshima, TeruPrincipal Associate in Medicine31160565Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, Pages M, Balboni Iniguez A, Paolella BR, Meng A, Sinai C, Roti G, Dharia NV, Creech A, Tanenbaum B, Khadka P, Tracy A, Tiv HL, Hong AL, Coy S, Rashid R, Lin JR, Cowley GS, Lam FC, Goodale A, Lee Y, Schoolcraft K, Vazquez F, Hahn WC, Tsherniak A, Bradner JE, Yaffe MB, Milde T, Pfister SM, Qi J, Schenone M, Carr SA, Ligon KL, Kieran MW, Santagata S, Olson JM, Gokhale PC, Jaffe JD, Root DE, Stegmaier K, Johannessen CM, Beroukhim RNature communicationsNeuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.Nat Commun2019-06-03T00:00:002019Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.JD11JamesDeCaprioJames A. DeCaprio, M.D.42.33789600000000-71.1072493000000048267DeCaprio, JamesProfessor of MedicineSHO1StuartOrkinStuart Holland Orkin, M.D.42.33789600000000-71.1072493000000056992Orkin, StuartDavid G. Nathan Distinguished Professor of PediatricsKS9KimberlyStegmaierKimberly Stegmaier, M.D.42.33789600000000-71.1072493000000058081Stegmaier, KimberlyProfessor of PediatricsNCM4NikhilMunshiNikhil C Munshi, M.B.,B.S., M.D.42.33789600000000-71.1072493000000072797Munshi, NikhilProfessor of Medicine11120selected publications2.726840.00340384505research areas1.356210.024513135coauthor of74.403914.243660similar toKP5KorneliaPolyakKornelia Polyak, M.D., Ph.D.42.33789600000000-71.1072493000000076355Polyak, KorneliaProfessor of MedicineMP37MarkPomerantzMark M Pomerantz, M.D.42.33789600000000-71.1072493000000052766Pomerantz, MarkAssistant Professor of MedicineEDJ1EricJacobsenEric David Jacobsen, M.D.42.33789600000000-71.1072493000000025543Jacobsen, EricAssistant Professor of MedicineGL78Gwo-Shu MaryLeeGwo-Shu Mary Lee, Ph.D.42.33789600000000-71.1072493000000086170Lee, Gwo-Shu MaryResearch Associate in MedicineAuthorship 1168483631262315Wang RH, Zhang H, Zhang Y, Li XN, Shen XX, Qi JJ, Fan GH, Xiang XY, Zhan ZF, Chen ZW, Ma XJVirology journalDevelopment and evaluation of recombinase-aided amplification assays incorporating competitive internal controls for detection of human adenovirus serotypes 3 and 7. Virol J. 2019 07 01; 16(1):86.Virol J2019-07-01T00:00:002019Development and evaluation of recombinase-aided amplification assays incorporating competitive internal controls for detection of human adenovirus serotypes 3 and 7.31260717Tatetsu H, Armant M, Wang F, Gao C, Ueno S, Tian X, Federation A, Qi J, Bradner J, Tenen DG, Chai LExperimental hematologyMaintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Exp Hematol. 2019 07; 75:53-63.e11.Exp Hematol2019-06-28T00:00:002019Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).RIH2RobertHaddadRobert I. Haddad, M.D.42.33789600000000-71.1072493000000015867Haddad, RobertProfessor of Medicine31494268Kong W, Hayashi T, Fiches G, Xu Q, Li MZ, Que J, Liu S, Zhang W, Qi J, Santoso N, Elledge SJ, Zhu JGenomics, proteomics & bioinformaticsDiversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions. Genomics Proteomics Bioinformatics. 2019 06; 17(3):319-331.Genomics Proteomics Bioinformatics2019-09-05T00:00:002019Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions.Authorship 1199158531479240Du QC, Yang MT, Yang JK, Zhang P, Qi JQ, Bai L, Li Z, Chen JY, Liu RQ, Feng XM, Huang ZD, Masese T, Ma YW, Huang WACS applied materials & interfacesBendable Network Built with Ultralong Silica Nanowires as a Stable Separator for High-Safety and High-Power Lithium-Metal Batteries. ACS Appl Mater Interfaces. 2019 Sep 25; 11(38):34895-34903.ACS Appl Mater Interfaces2019-09-12T00:00:002019Bendable Network Built with Ultralong Silica Nanowires as a Stable Separator for High-Safety and High-Power Lithium-Metal Batteries.true1Professor of MedicineProfessor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Research Associate in MedicineResearch Associate in Medicinetrue1Kraft Family Professor of MedicineKraft Family Professor of Medicinetrue1Principal Associate in MedicinePrincipal Associate in Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Professor of PediatricsProfessor of Pediatricstrue1David G. Nathan Professor of PediatricsDavid G. Nathan Professor of Pediatricstrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1R.J. Corman Professor of MedicineR.J. Corman Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicine2025-02-28DUCKETT, DEREK RONALD ;QI, JUN2020-03-01Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell LymphomaR01CA233601Co-Principal Investigator32407673Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi JMolecular cellUsing Chemical Epigenetics to Target Cancer. Mol Cell. 2020 06 18; 78(6):1086-1095.Mol Cell2020-05-13T00:00:002020Using Chemical Epigenetics to Target Cancer.32416067Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovic B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak KMolecular cellSynthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8.Mol Cell2020-05-15T00:00:002020Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.32393766Ge JY, Shu S, Kwon M, Jovanovic B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak KNature communicationsAcquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350.Nat Commun2020-05-11T00:00:002020Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.true1Associate Professor of PediatricsAssociate Professor of PediatricsAuthorship 1256598132559499Au YZ, Wang T, Sigua LH, Qi JCell chemical biologyPeptide-Based PROTAC: The Predator of Pathological Proteins. Cell Chem Biol. 2020 06 18; 27(6):637-639.Cell Chem Biol2020-06-18T00:00:002020Peptide-Based PROTAC: The Predator of Pathological Proteins.32516588Qi J, Shi YCancer cellSelective Targeting of Different Bromodomains by Small Molecules. Cancer Cell. 2020 06 08; 37(6):764-766.Cancer Cell2020-06-08T00:00:002020Selective Targeting of Different Bromodomains by Small Molecules.32603312Antolic A, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Lemieux ME, Conner DA, Lee DY, Qi J, Seidman JG, Bradner JE, Brown JD, Haldar SM, Seidman CE, Burke MAJCI insightBET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight. 2020 08 06; 5(15).JCI Insight2020-08-06T00:00:002020BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy.32826232Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debré I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, Roti G, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant ACancer discoveryThe Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discov. 2020 12; 10(12):1894-1911.Cancer Discov2020-08-21T00:00:002020The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.33972779Wu Z, Zhou J, Zhang X, Zhang Z, Xie Y, Liu JB, Ho ZV, Panda A, Qiu X, Cejas P, Cañadas I, Akarca FG, McFarland JM, Nagaraja AK, Goss LB, Kesten N, Si L, Lim K, Liu Y, Zhang Y, Baek JY, Liu Y, Patil DT, Katz JP, Hai J, Bao C, Stachler M, Qi J, Ishizuka JJ, Nakagawa H, Rustgi AK, Wong KK, Meyerson M, Barbie DA, Brown M, Long H, Bass AJNature geneticsReprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat Genet. 2021 06; 53(6):881-894.Nat Genet2021-05-10T00:00:002021Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.34107377Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, Weiss WA, Gustafson WCNeoplasia (New York, N.Y.)The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.Neoplasia2021-06-07T00:00:002021The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.34258103Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi JBlood cancer discoveryLysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387.Blood Cancer Discov2021-04-10T00:00:002021Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.34341479Pikman Y, Ocasio-Martinez N, Alexe G, Dimitrov B, Kitara S, Diehl FF, Robichaud AL, Conway AS, Ross L, Su A, Ling F, Qi J, Roti G, Lewis CA, Puissant A, Vander Heiden MG, Stegmaier KLeukemiaTargeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2022 02; 36(2):348-360.Leukemia2021-08-02T00:00:002021Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.34434504Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KCOncotargetCorrection: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2021 Aug 17; 12(17):1736.Oncotarget2021-08-17T00:00:002021Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.29490948Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino GE, Shah J, Niedzwicki D, Weber K, Park PMC, Alam MZ, Grazioli A, Haldar M, Xu M, Perry JA, Qi J, Eisinger-Mathason TSKCancer researchYAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res. 2018 05 15; 78(10):2705-2720.Cancer Res2018-02-28T00:00:002018YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis.34593523Yang J, Gao C, Liu M, Liu YC, Kwon J, Qi J, Tian X, Stein A, Liu YV, Kong NR, Wu Y, Yin S, Xi J, Chen Z, Kumari K, Wong H, Luo H, Silberstein LE, Thoms JAI, Unnikrishnan A, Pimanda JE, Tenen DG, Chai LCancer researchTargeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. Cancer Res. 2021 12 01; 81(23):6018-6028.Cancer Res2021-09-30T00:00:002021Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.34772733Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Conway AS, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest O, Easton J, Schönbrunn E, Bulyk ML, Abraham BJ, Stegmaier K, Look AT, Qi JCancer discoveryEP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discov. 2022 03 01; 12(3):730-751.Cancer Discov2022-03-01T00:00:002022EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.Authorship 142550130Authorship 14321562935100352Kozuka C, Efthymiou V, Sales VM, Zhou L, Osataphan S, Yuchi Y, Chimene-Weiss J, Mulla C, Isganaitis E, Desmond J, Sanechika S, Kusuyama J, Goodyear L, Shi X, Gerszten RE, Aguayo-Mazzucato C, Carapeto P, Teixeira SD, Sandoval D, Alonso-Curbelo D, Wu L, Qi J, Patti MEDiabetesBromodomain Inhibition Reveals FGF15/19 As a Target of Epigenetic Regulation and Metabolic Control. Diabetes. 2022 05 01; 71(5):1023-1033.Diabetes2022-05-01T00:00:002022Bromodomain Inhibition Reveals FGF15/19 As a Target of Epigenetic Regulation and Metabolic Control.35226736Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KPA, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BRBloodBET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.Blood2022-05-12T00:00:002022BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.35390276Zullow HJ, Sankar A, Ingram DR, Samé Guerra DD, D'Avino AR, Collings CK, Lazcano R, Wang WL, Liang Y, Qi J, Lazar AJ, Kadoch CMolecular cellThe FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. Mol Cell. 2022 05 05; 82(9):1737-1750.e8.Mol Cell2022-04-06T00:00:002022The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.35681054St Pierre R, Collings CK, Samé Guerra DD, Widmer CJ, Bolonduro O, Mashtalir N, Sankar A, Liang Y, Bi WL, Gerkes EH, Ramesh V, Qi J, Smith MJ, Meredith DM, Kadoch CNature geneticsSMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma. Nat Genet. 2022 06; 54(6):861-873.Nat Genet2022-06-09T00:00:002022SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.36305736Panditharatna E, Marques JG, Wang T, Trissal MC, Liu I, Jiang L, Beck A, Groves A, Dharia NV, Li D, Hoffman SE, Kugener G, Shaw ML, Mire HM, Hack OA, Dempster JM, Lareau C, Dai L, Sigua LH, Quezada MA, Stanton AJ, Wyatt M, Kalani Z, Goodale A, Vazquez F, Piccioni F, Doench JG, Root DE, Anastas JN, Jones KL, Conway AS, Stopka S, Regan MS, Liang Y, Seo HS, Song K, Bashyal P, Jerome WP, Mathewson ND, Dhe-Paganon S, Suvà ML, Carcaboso AM, Lavarino C, Mora J, Nguyen QD, Ligon KL, Shi Y, Agnihotri S, Agar NYR, Stegmaier K, Stiles CD, Monje M, Golub TR, Qi J, Filbin MGCancer discoveryBAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer Discov. 2022 12 02; 12(12):2880-2905.Cancer Discov2022-12-02T00:00:002022BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.36780189Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KCClinical cancer research : an official journal of the American Association for Cancer ResearchBRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clin Cancer Res. 2023 05 01; 29(9):1807-1821.Clin Cancer Res2023-05-01T00:00:002023BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.36894709Wei J, Patil A, Collings CK, Alfajaro MM, Liang Y, Cai WL, Strine MS, Filler RB, DeWeirdt PC, Hanna RE, Menasche BL, Ökten A, Peña-Hernández MA, Klein J, McNamara A, Rosales R, McGovern BL, Luis Rodriguez M, García-Sastre A, White KM, Qin Y, Doench JG, Yan Q, Iwasaki A, Zwaka TP, Qi J, Kadoch C, Wilen CBNature geneticsPharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. Nat Genet. 2023 03; 55(3):471-483.Nat Genet2023-03-09T00:00:002023Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.36944333Battistello E, Hixon KA, Comstock DE, Collings CK, Chen X, Rodriguez Hernaez J, Lee S, Cervantes KS, Hinkley MM, Ntatsoulis K, Cesarano A, Hockemeyer K, Haining WN, Witkowski MT, Qi J, Tsirigos A, Perna F, Aifantis I, Kadoch CMolecular cellStepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Mol Cell. 2023 04 20; 83(8):1216-1236.e12.Mol Cell2023-03-20T00:00:002023Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion.Authorship 15413563Authorship 154135744Authorship 15413582Authorship 154135919Authorship 15413607Authorship 154136112Authorship 154136222Authorship 15413637Authorship 154136428Authorship 154136510Authorship 15413666Authorship 154136722Authorship 154136821Authorship 154136917Authorship 15413705Authorship 154137115Authorship 15413729Authorship 154137319Authorship 154137412Authorship 154137514Authorship 15413763Authorship 154137729Authorship 15413787Authorship 154137910Authorship 154138013Authorship 15413818Authorship 15413824Authorship 154138331Authorship 15413846Authorship 154138512Authorship 15413866Authorship 15413878Authorship 15413884Authorship 154138926Authorship 154139021Authorship 154139131Authorship 154139215Authorship 154139326Authorship 154139416Authorship 154139514Authorship 15413966Authorship 15413975Authorship 154139854Authorship 154139915Authorship 154140020Authorship 154140131Authorship 15414024Authorship 154140316Authorship 15414046Authorship 154140522Authorship 154140615Authorship 15414077Authorship 154140812Authorship 154140912Authorship 154141015Authorship 154141111Authorship 154141214Authorship 154141313Authorship 154141411Authorship 15414154Authorship 15414166Authorship 15414175Authorship 154141810Authorship 15414199Authorship 154142026Authorship 15414211731285436Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, Wiest O, Yohe ME, Shern JF, Qi J, Khan JNature communicationsChemical genomics reveals histone deacetylases are required for core regulatory transcription. Nat Commun. 2019 07 08; 10(1):3004.Nat Commun2019-07-08T00:00:002019Chemical genomics reveals histone deacetylases are required for core regulatory transcription.31744829Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatlioglu E, Almonte C, Labbe K, Silver H, Rabin AR, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman PS, Velcheti V, Freeman GJ, Qi J, Miller G, Wong KKCancer discoveryIn Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. Cancer Discov. 2020 Feb; 10(2):270-287.Cancer Discov2019-11-19T00:00:002019In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.32661245Gier RA, Budinich KA, Evitt NH, Cao Z, Freilich ES, Chen Q, Qi J, Lan Y, Kohli RM, Shi JNature communicationsHigh-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nat Commun. 2020 Jul 13; 11(1):3455.Nat Commun2020-07-13T00:00:002020High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening.32730819Duan Q, Huang FL, Li SJ, Chen KZ, Gong L, Qi J, Yang ZH, Yang TL, Li F, Li CQNeuropharmacologyBET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2. Neuropharmacology. 2020 10 15; 177:108255.Neuropharmacology2020-07-28T00:00:002020BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2.34932262Jiang J, Sigua LH, Chan A, Kalra P, Pomerantz WCK, Schönbrunn E, Qi J, Georg GIChemMedChemDihydropyridine Lactam Analogs Targeting BET Bromodomains. ChemMedChem. 2022 01 05; 17(1):e202100407.ChemMedChem2021-12-21T00:00:002021Dihydropyridine Lactam Analogs Targeting BET Bromodomains.35363464Wang MY, Liow P, Guzman MIT, Qi JACS chemical biologyExploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics. ACS Chem Biol. 2022 04 15; 17(4):744-755.ACS Chem Biol2022-04-01T00:00:002022Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.35867655Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schönbrunn EJournal of medicinal chemistryBivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. J Med Chem. 2022 08 11; 65(15):10441-10458.J Med Chem2022-07-22T00:00:002022Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.35941525Jiang J, Zhao PL, Sigua LH, Chan A, Schönbrunn E, Qi J, Georg GIArchiv der Pharmazie1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains. Arch Pharm (Weinheim). 2022 Nov; 355(11):e2200288.Arch Pharm (Weinheim)2022-08-08T00:00:0020221,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.37075745Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan LN, Lee J, Zhang XH, Rosen ST, Müschen M, Qi J, Chen J, Hiom K, Bishop AJR, Chen CWAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis. Adv Sci (Weinh). 2023 06; 10(17):e2206584.Adv Sci (Weinh)2023-04-19T00:00:002023Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.33460788Huang FL, Li F, Zhang WJ, Li SJ, Yang ZH, Yang TL, Qi J, Duan Q, Li CQNeurobiology of learning and memoryBrd4 participates in epigenetic regulation of the extinction of remote auditory fear memory. Neurobiol Learn Mem. 2021 03; 179:107383.Neurobiol Learn Mem2021-01-15T00:00:002021Brd4 participates in epigenetic regulation of the extinction of remote auditory fear memory.33730585Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao JCell reportsTranscriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 03 16; 34(11):108870.Cell Rep2021-03-16T00:00:002021Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.35975457Zheng S, Lin J, Pang Z, Zhang H, Wang Y, Ma L, Zhang H, Zhang X, Chen M, Zhang X, Zhao C, Qi J, Cao L, Wang M, He X, Sheng RAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Aberrant Cholesterol Metabolism and Wnt/ß-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth. Adv Sci (Weinh). 2022 10; 9(28):e2200750.Adv Sci (Weinh)2022-08-17T00:00:002022Aberrant Cholesterol Metabolism and Wnt/ß-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth.29567778Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges SHaematologicaBET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica. 2018 06; 103(6):939-948.Haematologica2018-03-22T00:00:002018BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.30459933Zhu X, Holmsen E, Park S, Willingham MC, Qi J, Cheng SYOncotargetSynergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. Oncotarget. 2018 Oct 23; 9(83):35408-35421.Oncotarget2018-10-23T00:00:002018Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors.31409188Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, Enyart BY, Koch KA, Cavasin MA, Alexanian M, Song K, Qi J, Lemieux ME, Srivastava D, Lam MPY, Haldar SM, Lin CY, McKinsey TACirculation researchDynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circ Res. 2019 09 13; 125(7):662-677.Circ Res2019-08-14T00:00:002019Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.31691152Duan Q, Wu P, Liu Z, Xia F, Zhu L, Zheng Z, Yang T, Qi JEndocrineBET bromodomain inhibition suppresses adipogenesis in mice. Endocrine. 2020 01; 67(1):264-267.Endocrine2019-11-05T00:00:002019BET bromodomain inhibition suppresses adipogenesis in mice.32646968Li F, Ng WL, Luster TA, Hu H, Sviderskiy VO, Dowling CM, Hollinshead KER, Zouitine P, Zhang H, Huang Q, Ranieri M, Wang W, Fang Z, Chen T, Deng J, Zhao K, So HC, Khodadadi-Jamayran A, Xu M, Karatza A, Pyon V, Li S, Pan Y, Labbe K, Almonte C, Poirier JT, Miller G, Possemato R, Qi J, Wong KKCancer researchEpigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. Cancer Res. 2020 09 01; 80(17):3556-3567.Cancer Res2020-07-09T00:00:002020Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer.34037670Milner JJ, Toma C, Quon S, Omilusik K, Scharping NE, Dey A, Reina-Campos M, Nguyen H, Getzler AJ, Diao H, Yu B, Delpoux A, Yoshida TM, Li D, Qi J, Vincek A, Hedrick SM, Egawa T, Zhou MM, Crotty S, Ozato K, Pipkin ME, Goldrath AWThe Journal of experimental medicineBromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection. J Exp Med. 2021 08 02; 218(8).J Exp Med2021-05-26T00:00:002021Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection.34358447Cao Z, Budinich KA, Huang H, Ren D, Lu B, Zhang Z, Chen Q, Zhou Y, Huang YH, Alikarami F, Kingsley MC, Lenard AK, Wakabayashi A, Khandros E, Bailis W, Qi J, Carroll MP, Blobel GA, Faryabi RB, Bernt KM, Berger SL, Shi JMolecular cellZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Mol Cell. 2021 09 02; 81(17):3604-3622.e10.Mol Cell2021-08-05T00:00:002021ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.35217626Ren Z, Kim A, Huang YT, Pi WC, Gong W, Yu X, Qi J, Jin J, Cai L, Roeder RG, Chen WY, Wang GGProceedings of the National Academy of Sciences of the United States of AmericaA PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022 03 01; 119(9).Proc Natl Acad Sci U S A2022-03-01T00:00:002022A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.36193052Pingul BY, Huang H, Chen Q, Alikarami F, Zhang Z, Qi J, Bernt KM, Berger SL, Cao Z, Shi JiScienceDissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. iScience. 2022 Oct 21; 25(10):105139.iScience2022-09-15T00:00:002022Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia.32832623Zhou D, Hayashi T, Jean M, Kong W, Fiches G, Biswas A, Liu S, Yosief HO, Zhang X, Bradner J, Qi J, Zhang W, Santoso N, Zhu JScience advancesInhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo. Sci Adv. 2020 07; 6(29):eaba1941.Sci Adv2020-07-15T00:00:002020Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo.33872011Muthengi A, Wimalasena VK, Yosief HO, Bikowitz MJ, Sigua LH, Wang T, Li D, Gaieb Z, Dhawan G, Liu S, Erickson J, Amaro RE, Schönbrunn E, Qi J, Zhang WJournal of medicinal chemistryDevelopment of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors. J Med Chem. 2021 05 13; 64(9):5787-5801.J Med Chem2021-04-19T00:00:002021Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.36332631Sevinç K, Sevinç GG, Cavga AD, Philpott M, Kelekçi S, Can H, Cribbs AP, Yildiz AB, Yilmaz A, Ayar ES, Arabaci DH, Dunford JE, Ata D, Sigua LH, Qi J, Oppermann U, Onder TTStem cell reportsBRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming. Stem Cell Reports. 2022 12 13; 17(12):2629-2642.Stem Cell Reports2022-11-03T00:00:002022BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming.true1David G. Nathan Distinguished Professor of PediatricsDavid G. Nathan Distinguished Professor of Pediatrics23430699Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier KCancer discoveryTargeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar; 3(3):308-23.Cancer Discov2013-02-21T00:00:002013Targeting MYCN in neuroblastoma by BET bromodomain inhibition.23706636Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier KChemistry & biologySelective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 2013 May 23; 20(5):713-25.Chem Biol2013-05-23T00:00:002013Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.24045185Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KKClinical cancer research : an official journal of the American Association for Cancer ResearchEfficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6183-92.Clin Cancer Res2013-09-17T00:00:002013Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.Authorship 6896605Authorship 68965513Authorship 6937951024332044Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JECancer cellDiscovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013 Dec 09; 24(6):777-90.Cancer Cell2013-12-09T00:00:002013Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.CK161CigallKadochCigall Kadoch, Ph.D.123898Kadoch, CigallAssociate Professor of Pediatrics24336317Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Lovén J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RANature biotechnologyGenome-wide localization of small molecules. Nat Biotechnol. 2014 Jan; 32(1):92-6.Nat Biotechnol2013-12-15T00:00:002013Genome-wide localization of small molecules.Authorship 7234533Authorship 7127264Authorship 723409624444712Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LCCancer discoveryRapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014 Mar; 4(3):318-33.Cancer Discov2014-01-20T00:00:002014RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.Authorship 7273137Authorship 728367324435449Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DAMolecular cancer therapeuticsTargeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther. 2014 May; 13(5):1194-205.Mol Cancer Ther2014-01-16T00:00:002014Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.24435446Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KNMolecular cancer therapeuticsHighly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May; 13(5):1142-54.Mol Cancer Ther2014-01-16T00:00:002014Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.24973920Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, Ponnuswami A, Monje M, Atwood SX, Whitson RJ, Mitra S, Cheshier SH, Qi J, Beroukhim R, Tang JY, Wechsler-Reya R, Oro AE, Link BA, Bradner JE, Cho YJNature medicineEpigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul; 20(7):732-40.Nat Med2014-06-29T00:00:002014Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.Authorship 310271024552990Reynolds C, Roderick JE, LaBelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, Look AT, Walensky LD, Kelliher MA, Gutierrez ALeukemiaRepression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2014 Sep; 28(9):1819-27.Leukemia2014-02-20T00:00:002014Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.25053825Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KNMolecular cancer therapeuticsBET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct; 13(10):2315-27.Mol Cancer Ther2014-07-22T00:00:002014BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.Authorship 7692901325314271McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JEJournal of medicinal chemistryBiased multicomponent reactions to develop novel bromodomain inhibitors. J Med Chem. 2014 Nov 13; 57(21):9019-27.J Med Chem2014-10-31T00:00:002014Biased multicomponent reactions to develop novel bromodomain inhibitors.25320008Chan CT, Qi J, Smith W, Paranol R, Mazitschek R, West N, Reeves R, Chiosis G, Schreiber SL, Bradner JE, Paulmurugan R, Gambhir SSCancer researchSyntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. Cancer Res. 2014 Dec 15; 74(24):7475-86.Cancer Res2014-10-15T00:00:002014Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.25822366Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SANature medicineDOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43.Nat Med2015-03-30T00:00:002015DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.25751058Schölz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, Jensen LJ, Streicher W, McCarthy AR, Westwood NJ, Lain S, Cox J, Matthias P, Mann M, Bradner JE, Choudhary CNature biotechnologyAcetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015 Apr; 33(4):415-23.Nat Biotechnol2015-03-09T00:00:002015Acetylation site specificities of lysine deacetylase inhibitors in human cells.25688158Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SAClinical cancer research : an official journal of the American Association for Cancer ResearchSelective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res. 2015 May 15; 21(10):2348-58.Clin Cancer Res2015-02-16T00:00:002015Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.25652456An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, Yi S, Xu Y, Feng X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Anderson KC, Qiu LClinical cancer research : an official journal of the American Association for Cancer ResearchThe impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015 May 01; 21(9):2148-56.Clin Cancer Res2015-02-04T00:00:002015The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.25397901Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JEACS chemical biologyStructure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74.ACS Chem Biol2015-01-15T00:00:002015Structure-guided DOT1L probe optimization by label-free ligand displacement.DFCI26174566Tanaka M, Roberts JM, Qi J, Bradner JEPharmaceutical patent analystInhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharm Pat Anal. 2015; 4(4):261-84.Pharm Pat Anal2015-01-01T00:00:002015Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).26117538Hu YJ, Belaghzal H, Hsiao WY, Qi J, Bradner JE, Guertin DA, Sif S, Imbalzano ANNucleic acids researchTranscriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucleic Acids Res. 2015 Sep 18; 43(16):7790-804.Nucleic Acids Res2015-06-27T00:00:002015Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6.26254443Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KNBloodSynergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24; 126(13):1565-74.Blood2015-08-07T00:00:002015Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.26735014Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak KNatureResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016 Jan 21; 529(7586):413-417.Nature2016-01-06T00:00:002016Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.26829750Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BENature geneticsAn oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016 Mar; 48(3):265-72.Nat Genet2016-02-01T00:00:002016An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.26148704Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KNLeukemiaHEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. 2016 Feb; 30(2):504-8.Leukemia2015-06-15T00:00:002015HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.25961927Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, Arnoletti JP, Richardson JH, Chen D, Hanna CA, Cramer SL, Yang ES, Qi J, Bradner JE, Yoon KJOncogeneThe BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. 2016 Feb 18; 35(7):833-45.Oncogene2015-05-11T00:00:002015The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.26855180Duan Q, Mao X, Xiao Y, Liu Z, Wang Y, Zhou H, Zhou Z, Cai J, Xia K, Zhu Q, Qi J, Huang H, Plutzky J, Yang TBiochimica et biophysica actaSuper enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. Biochim Biophys Acta. 2016 Apr; 1859(4):564-71.Biochim Biophys Acta2016-02-05T00:00:002016Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation.27135738Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NENature medicineAn oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med. 2016 06; 22(6):632-40.Nat Med2016-05-02T00:00:002016An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.2Assistant Professor1Associate Professor0Full Professor5Other Faculty27280396Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen JCancer researchEradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80.Cancer Res2016-06-08T00:00:002016Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.27422033Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, Porcu P, Caligiuri MACancer discoveryMechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discov. 2016 09; 6(9):986-1005.Cancer Discov2016-07-15T00:00:002016Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.27312177Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF, Hammerman PS, Brown M, Cichowski K, Long H, Bradner JE, Wong KKCancer discoveryOncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discov. 2016 09; 6(9):1006-21.Cancer Discov2016-06-16T00:00:002016Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.2017-06-30QI, JUN2012-09-26Selective inhibition of BRDT for male contraceptionU01HD076508Authorship 324793527630126Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, Fujiwara Y, Qi J, Cheloni G, Das PP, Nguyen M, Li S, Bradner JE, Orkin SHCancer discoveryChronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discov. 2016 11; 6(11):1237-1247.Cancer Discov2016-09-14T00:00:002016Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.2023-05-31ARMSTRONG, SCOTT A ;QI, JUN2012-09-25Targeting DOT1L for Degradation in MLL-rearranged LeukemiaR01CA17674527799547Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JEProceedings of the National Academy of Sciences of the United States of AmericaDiscovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.Proc Natl Acad Sci U S A2016-10-31T00:00:002016Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.450 Brookline AveDana-Farber Cancer InstituteL C-2210450 Brookline AveBoston02215MA28024402Cappel D, Hall ML, Lenselink EB, Beuming T, Qi J, Bradner J, Sherman WJournal of chemical information and modelingRelative Binding Free Energy Calculations Applied to Protein Homology Models. J Chem Inf Model. 2016 12 27; 56(12):2388-2400.J Chem Inf Model2016-11-18T00:00:002016Relative Binding Free Energy Calculations Applied to Protein Homology Models.27544600Duan Q, Mao X, Liao C, Zhou H, Sun Z, Deng X, Hu Q, Qi J, Zhang G, Huang H, Plutzky J, Yang TInternational journal of cardiologyInhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice. Int J Cardiol. 2016 Nov 15; 223:428-432.Int J Cardiol2016-08-14T00:00:002016Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice.28275007Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna JEMBO molecular medicineGene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med. 2017 04; 9(4):482-497.EMBO Mol Med2017-04-01T00:00:002017Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.28535045Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCKJournal of medicinal chemistryBET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. J Med Chem. 2017 06 22; 60(12):4805-4817.J Med Chem2017-06-07T00:00:002017BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.28581522Song Y, Li S, Ray A, Das DS, Qi J, Samur MK, Tai YT, Munshi N, Carrasco RD, Chauhan D, Anderson KCOncogeneBlockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017 10 05; 36(40):5631-5638.Oncogene2017-06-05T00:00:002017Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.09/2006University of MichiganAnn Arbor, MIUniversity of Michigan, ChemistryPh.D.ChemistryAuthorship 9923255Authorship 99232612Authorship 9923277Authorship 99232823Authorship 9923295Authorship 9923308Authorship 9923312Authorship 99233214Authorship 9923337Authorship 9923348Authorship 9923357Authorship 99233610Authorship 9923372Authorship 9923386Authorship 99233910Authorship 99234011Authorship 99234113Authorship 99234222Authorship 9923434Authorship 9923443Authorship 9923464Authorship 9923474Authorship 99234814Authorship 99235010Authorship 9923516Authorship 9923528Authorship 99235319Authorship 9923563Authorship 9923572Authorship 9923583Authorship 99235922Authorship 9923601027440272Zhu X, Enomoto K, Zhao L, Zhu YJ, Willingham MC, Meltzer P, Qi J, Cheng SYClinical cancer research : an official journal of the American Association for Cancer ResearchBromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clin Cancer Res. 2017 Jan 15; 23(2):430-440.Clin Cancer Res2016-07-20T00:00:002016Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.27717711Duan Q, Xiao Y, Zhu L, Liu Z, Mao X, Zhou Z, Liao C, Cai J, Huang F, Liu Z, Zeng J, Xia K, Chang C, Qi J, Chen Z, Huang H, Yang TBiochimica et biophysica actaBET bromodomain is a novel regulator of TAZ and its activity. Biochim Biophys Acta. 2016 12; 1859(12):1527-1537.Biochim Biophys Acta2016-10-04T00:00:002016BET bromodomain is a novel regulator of TAZ and its activity.28368473Enomoto K, Zhu X, Park S, Zhao L, Zhu YJ, Willingham MC, Qi J, Copland JA, Meltzer P, Cheng SYThe Journal of clinical endocrinology and metabolismTargeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 07 01; 102(7):2268-2280.J Clin Endocrinol Metab2017-07-01T00:00:002017Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.27545270Xiao Y, Liu Z, Liao C, Mao X, Cai J, Xia K, Qi J, Huang H, Yang T, Duan QLeukemia & lymphomaInhibition of BET bromodomain improves anemia in APCmin mice. Leuk Lymphoma. 2017 04; 58(4):989-992.Leuk Lymphoma2016-08-22T00:00:002016Inhibition of BET bromodomain improves anemia in APCmin mice.28701475Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WGScience translational medicineHIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Sci Transl Med. 2017 07 12; 9(398).Sci Transl Med2017-07-12T00:00:002017HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.Authorship 9981983Authorship 9981993Authorship 9982008Authorship 99820110Authorship 9982028Authorship 998203228708596Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KCOncotargetHDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Jul 05.Oncotarget2017-07-05T00:00:002017HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.28805820Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei WNature medicineProstate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med. 2017 Sep; 23(9):1063-1071.Nat Med2017-08-14T00:00:002017Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.29113288Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KCOncotargetHDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Oct 06; 8(46):80109-80123.Oncotarget2017-07-05T00:00:002017HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.29158376Roti G, Qi J, Kitara S, Sanchez-Martin M, Saur Conway A, Varca AC, Su A, Wu L, Kung AL, Ferrando AA, Bradner JE, Stegmaier KThe Journal of experimental medicineLeukemia-specific delivery of mutant NOTCH1 targeted therapy. J Exp Med. 2018 01 02; 215(1):197-216.J Exp Med2017-11-20T00:00:002017Leukemia-specific delivery of mutant NOTCH1 targeted therapy.29158558Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KCLeukemiaProtein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 04; 32(4):996-1002.Leukemia2017-11-21T00:00:002017Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.29192133Erwin GS, Grieshop MP, Ali A, Qi J, Lawlor M, Kumar D, Ahmad I, McNally A, Teider N, Worringer K, Sivasankaran R, Syed DN, Eguchi A, Ashraf M, Jeffery J, Xu M, Park PMC, Mukhtar H, Srivastava AK, Faruq M, Bradner JE, Ansari AZScience (New York, N.Y.)Synthetic transcription elongation factors license transcription across repressive chromatin. Science. 2017 12 22; 358(6370):1617-1622.Science2017-11-30T00:00:002017Synthetic transcription elongation factors license transcription across repressive chromatin.29202477Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier KThe Journal of clinical investigationCRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462.J Clin Invest2017-12-04T00:00:002017CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.29249691Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RLCancer cellDual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018 01 08; 33(1):29-43.e7.Cancer Cell2017-12-14T00:00:002017Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.29249359Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen JCellR-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell. 2018 01 11; 172(1-2):90-105.e23.Cell2017-12-14T00:00:002017R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.22901802Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JECellSmall-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17; 150(4):673-84.Cell2012-08-17T00:00:002012Small-molecule inhibition of BRDT for male contraception.22904298Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DMBloodBET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 04; 120(14):2843-52.Blood2012-08-17T00:00:002012BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.